Inclusion Criteria:  Histologically or cytologically confirmed pancreatic adenocarcinoma of exocrine pancreas that is metastatic, unresectable, or recurrent At least one measurable lesion according to Response Evaluation Criteria in Solid Tumor V1.1 Documented disease progression after one prior gemcitabine-based therapy OR one FOLFIRINOX and gemcitabine combination therapy Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1 or Karnofsky performance status (KPS) ≥ 70 Adequate hepatic, renal and bone marrow function  Exclusion Criteria:  Clinically significant decrease in performance status (medical records) within 2 weeks of intended first dose administration Clinically significant GI disorders Severe arterial thromboembolic events less than 6 months before inclusion Prior Whole Brain Radiation Therapy (WBRT) Evidence of brain metastases NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure (defined as ≥ 160/100 mm Hg) Use of strong CYP3A4 inducers or inhibitors and/or UGT1A1 inhibitors within 14 days prior to Visit 1/Baseline visit.